GeneDx Holdings Corp. (WGS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GeneDx Holdings Corp. (WGS) trades at $82.55 with AI Score 31/100 (Grade D). GeneDx Holdings Corp. is a patient-centered health intelligence company transforming healthcare through AI and machine learning applied to clinical and genomic data. Market cap: $2.46B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 9, 2026WGS stock analysis for 2026: Analysts have set a consensus price target of $156.67 for GeneDx Holdings Corp., suggesting 89.8% upside from the current price of $82.55. The AI MoonshotScore is 31/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
WGS: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
GeneDx Holdings Corp. (WGS) Healthcare & Pipeline Overview
GeneDx Holdings Corp. leverages AI and machine learning through its Centrellis platform to analyze clinical and genomic data, aiming to transform healthcare by creating dynamic models of human health. As a patient-centered health intelligence company, GeneDx provides science-driven solutions to address critical medical needs within the healthcare information services sector.
What Is the Investment Thesis for WGS?
GeneDx Holdings Corp. presents an investment opportunity centered on its innovative Centrellis platform and its application of AI and machine learning in healthcare. With a market capitalization of $2.46B, the company operates in the high-growth healthcare information services sector. Key value drivers include the expansion of its Centrellis platform and increasing adoption by healthcare providers. Upcoming catalysts include potential partnerships with pharmaceutical companies and further development of its AI-driven diagnostic tools. However, the company's negative profit margin of -17.6% and a high beta of 2.19 indicate significant risk, requiring careful consideration of market volatility and financial performance.
Based on FMP financials and quantitative analysis
WGS Key Highlights
Market capitalization of $2.46B, reflecting investor confidence in the company's growth potential.
- Gross margin of 68.3%, indicating strong pricing power and efficient service delivery.
- Negative profit margin of -17.6%, highlighting the need for improved cost management and revenue generation.
- Beta of 2.19, indicating high volatility compared to the broader market.
- No dividend yield, suggesting that the company is reinvesting earnings for growth.
Who Are WGS's Competitors?
WGS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IMVT Immunovant, Inc. | $44.96 | +1.49% | $9.28B | — |
| OSCR Oscar Health, Inc. | $31.57 | -2.26% | $8.19B | 97 |
| CRNX Crinetics Pharmaceuticals, Inc. | $84.69 | -0.04% | $8.97B | — |
| PRVA Privia Health Group, Inc. | $21.49 | -0.14% | $2.71B | 34 |
| NAMS NewAmsterdam Pharma Company N.V. | $28.53 | +4.70% | $3.34B | 51 |
| PGNY Progyny, Inc. | $25.53 | -0.70% | $2.00B | 91 |
| ONEM ONEM | $16.47 | +0.00% | $3.40B | 55 |
| OMCL Omnicell, Inc. | $35.67 | -2.09% | $1.62B | 80 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WGS's Key Strengths?
Innovative Centrellis platform leveraging AI and machine learning.
- Strong focus on personalized medicine and data-driven healthcare.
- Experienced leadership team with expertise in healthcare and technology.
- Growing database of clinical and genomic data.
What Are WGS's Weaknesses?
Negative profit margin indicating financial challenges.
- High beta suggesting significant market volatility.
- Reliance on partnerships for revenue generation.
- Limited geographic presence.
What Could Drive WGS Stock Higher?
Potential partnerships with pharmaceutical companies to leverage Centrellis for drug discovery and development.
- Development and launch of new AI-driven diagnostic tools.
- Expansion of the Centrellis platform to include additional data sources and functionalities.
- Increasing adoption of Centrellis by healthcare providers and researchers.
- Growing focus on personalized medicine driving demand for AI-driven solutions.
What Are the Key Risks for WGS?
Negative return on equity (-38.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 41.4 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Intense competition in the healthcare information services sector.
- Regulatory changes impacting data privacy and security.
- Economic downturn affecting healthcare spending.
- Negative profit margin indicating financial challenges.
- High beta suggesting significant market volatility.
What Are the Growth Opportunities for WGS?
- Expansion of Centrellis Platform: GeneDx has a significant opportunity to expand the capabilities and reach of its Centrellis health intelligence platform. By integrating additional data sources and developing new AI-driven applications, Centrellis can become an indispensable tool for healthcare providers and researchers. The market for AI in healthcare is projected to reach $45.2 billion by 2026, offering a substantial growth runway for GeneDx.
- Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to leverage Centrellis for drug discovery and development represents a major growth opportunity. By providing AI-driven insights into disease mechanisms and patient responses, GeneDx can accelerate the development of new therapies and improve clinical trial outcomes. This strategic direction aligns with the industry's increasing focus on precision medicine and personalized treatments.
- Development of AI-Driven Diagnostic Tools: GeneDx can further capitalize on its AI capabilities by developing diagnostic tools that enable earlier and more accurate detection of diseases. These tools can be integrated into clinical workflows to improve patient outcomes and reduce healthcare costs.
- Geographic Expansion: Expanding its operations beyond its current geographic footprint represents another key growth opportunity for GeneDx. By targeting new markets and establishing partnerships with local healthcare providers, GeneDx can increase its customer base and revenue streams.
- Personalized Medicine Initiatives: The increasing focus on personalized medicine creates a favorable environment for GeneDx's AI-driven approach. By leveraging its Centrellis platform to tailor treatments to individual patients, GeneDx can improve outcomes and reduce healthcare costs. The personalized medicine market is expected to reach $2.4 trillion by 2028, providing a substantial growth opportunity for GeneDx.
What Are WGS's Competitive Advantages?
- Proprietary Centrellis health intelligence platform.
- Expertise in applying AI and machine learning to healthcare data.
- Strong relationships with healthcare providers and pharmaceutical companies.
- Large and growing database of clinical and genomic data.
What Does WGS Do?
Founded in October 2015 by Eric Schadt and headquartered in Stamford, CT, GeneDx Holdings Corp. operates as a patient-centered health intelligence company. The company is dedicated to transforming healthcare by applying advanced artificial intelligence (AI) and machine learning techniques to vast, multidimensional, and longitudinal clinical and genomic data sets. This approach enables GeneDx to construct dynamic models of human health, ultimately defining optimal and individualized health trajectories for patients. At the core of GeneDx's operations is its Centrellis health intelligence platform. This platform is designed to generate a more comprehensive and nuanced understanding of both disease and wellness. By synthesizing complex data, Centrellis provides science-driven solutions targeted at addressing some of the most pressing medical challenges. GeneDx's focus on leveraging data-driven insights positions it as a key player in the evolving landscape of healthcare information services, aiming to improve patient outcomes and healthcare delivery through innovative technology.
What Products and Services Does WGS Offer?
- Applies AI and machine learning to clinical and genomic data.
- Develops dynamic models of human health.
- Defines individualized health trajectories.
- Offers the Centrellis health intelligence platform.
- Provides science-driven solutions for medical needs.
- Transforms healthcare through data-driven insights.
How Does WGS Make Money?
- Generates revenue through subscriptions to the Centrellis platform.
- Partners with pharmaceutical companies for drug discovery and development.
- Offers AI-driven diagnostic tools to healthcare providers.
- Provides personalized medicine solutions based on genomic data.
What Industry Does WGS Operate In?
GeneDx Holdings Corp. operates within the rapidly expanding healthcare information services sector. This industry is characterized by the increasing adoption of AI and machine learning technologies to improve healthcare outcomes and reduce costs. The competitive landscape includes companies like Immunovant, Inc. (IMVT) and Oscar Health, Inc. (OSCR), each focusing on different aspects of healthcare innovation. GeneDx's unique approach of applying AI to multidimensional clinical and genomic data positions it to capitalize on the growing demand for personalized and data-driven healthcare solutions.
Who Are WGS's Key Customers?
- Healthcare providers seeking to improve patient outcomes.
- Pharmaceutical companies engaged in drug discovery and development.
- Researchers studying disease mechanisms and personalized medicine.
- Patients seeking personalized treatment plans.
GeneDx Holdings Corp. (WGS) Valuation Context
Valued at $2.46B, WGS is classified as a mid-cap stock. Relative to its peer group, WGS's quantitative score of 31/100 is below the peer average of 61/100.
WGS Revenue & Earnings Trend
In Q2 2026, WGS generated $114.4M in top-line revenue, marking a sequential increase of 11.9%. The company recorded a net loss of $17.7M, with diluted EPS of $-0.60. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, WGS averaged $-0.91 in diluted EPS.
Company Profile
GeneDx Holdings Corp. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Stamford, US. The company is led by CEO Katherine A. Stueland. WGS has traded publicly since 2020.
Key Financial Metrics
Return on equity for GeneDx Holdings Corp. stands at -38.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -22.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.30 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
GeneDx Holdings Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.19 places it in the grey zone, a middle ground that warrants monitoring.
Earnings Track Record
GeneDx Holdings Corp. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 270.8% above estimates on average.
Forward Outlook
Wall Street analysts project GeneDx Holdings Corp. revenue of about $481.3M for fiscal 2026, with EPS near $-0.03. The estimate reflects 7 contributing analysts.
WGS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insider buying has increased recently, indicating confidence from leadership in the company's future.
- Positive community sentiment has emerged, with discussions highlighting GeneDx's innovative genetic testing solutions.
- Recent collaborations with healthcare providers have strengthened market perception and opened new revenue channels.
- The growing awareness and demand for genetic testing in personalized medicine are seen as long-term growth drivers for the company.
Bear Case
- Concerns over regulatory hurdles in the genetic testing market have surfaced, causing apprehension among investors.
- Social sentiment reflects skepticism about the company's ability to scale operations effectively amidst increasing competition.
- Recent earnings reports showed mixed results, leading to questions about the sustainability of growth.
- Some community members express doubts about the company's long-term business model and its adaptability to market changes.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $114M | -$18M | -$0.60 |
| Q1 2026 | $102M | -$63M | -$2.16 |
| Q4 2025 | $121M | -$18M | -$0.59 |
| Q3 2025 | $117M | -$8M | -$0.27 |
Based on FMP financials and quantitative analysis
WGS Latest News
No recent news available for WGS.
WGS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for WGS.
Price Targets
Consensus target: $156.67
WGS MoonshotScore
What does this score mean?
The MoonshotScore rates WGS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest GeneDx Holdings Corp. Analysis
Leadership: Katherine A. Stueland
CEO
Katherine A. Stueland is the CEO of GeneDx Holdings Corp., bringing extensive experience in healthcare management and strategic leadership. Prior to joining GeneDx, she held key leadership positions at various healthcare organizations, focusing on driving innovation and improving patient outcomes. Her background includes a strong track record in business development, operational efficiency, and market expansion. She is known for her ability to build high-performing teams and foster a culture of innovation.
Track Record: Under Katherine A. Stueland's leadership, GeneDx Holdings Corp. has focused on expanding the capabilities of its Centrellis platform and forging strategic partnerships to drive revenue growth. She has overseen the development of new AI-driven diagnostic tools and the expansion of the company's geographic reach. Her tenure has been marked by a commitment to leveraging data-driven insights to transform healthcare and improve patient outcomes.
GeneDx Holdings Corp. Healthcare Stock: Key Questions Answered
What does the AI Score mean for WGS?
WGS holds an AI Score of 31/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. GeneDx Holdings Corp. is a patient-centered health intelligence company transforming healthcare through AI and machine learning applied to clinical and genomic data. Their Centrellis platform aims …
What does GeneDx Holdings Corp. do?
GeneDx Holdings Corp. is a patient-centered health intelligence company that transforms healthcare by applying AI and machine learning to multidimensional clinical and genomic data. The company's Centrellis platform generates dynamic models of human health, providing science-driven solutions to pressing medical needs.
What do analysts say about WGS stock?
Analyst consensus on GeneDx Holdings Corp. (WGS) reflects a mixed outlook, acknowledging the company's innovative approach to healthcare through AI and machine learning. Key valuation metrics and growth considerations include the potential for revenue growth driven by the expansion of the Centrellis platform and strategic partnerships.
What are the main risks for WGS?
The main risks for GeneDx Holdings Corp. (WGS) include intense competition in the healthcare information services sector, regulatory changes impacting data privacy and security, and the potential for an economic downturn affecting healthcare spending. The company's negative profit margin and high beta also pose significant financial risks. Additionally, technological advancements could render current solutions obsolete, requiring continuous innovation and adaptation.
What are the key factors to evaluate for WGS?
GeneDx Holdings Corp. (WGS) holds an AI score of 31/100 (low). P/E: 41.4x vs the S&P 500's ~20-25x. Analysts target $156.67 (+90%). Not financial advice.
How frequently does WGS data refresh on this page?
WGS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven WGS's recent stock price performance?
GeneDx Holdings Corp. (WGS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Centrellis platform leveraging AI and machine learning. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider WGS overvalued or undervalued right now?
GeneDx Holdings Corp. (WGS) trades at 41.4x earnings. Analysts target $156.67 (+90%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research WGS before investing?
Before investing in GeneDx Holdings Corp. (WGS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Market projections are based on industry reports and analyst estimates.
- This analysis is for informational purposes only and does not constitute investment advice.